Intellectual Property Rights and Global Health Access

Intellectual property rights form a cornerstone of biopharmaceutical innovation, granting exclusive rights to inventors in exchange for public disclosure. Within the framework of the World Trade Organization’s TRIPS Agreement, patent protection has been harmonised across nearly every jurisdiction, delivering a predictable environment for research and development investment. However, the extension of monopolies on essential medicines can hinder access for low- and middle-income populations. To reconcile incentives for novel therapies with public health needs, a range of flexibilities—most notably compulsory licensing, patent oppositions and voluntary licensing arrangements—has been embedded into international and national legal instruments. Recent discourse emphasises a pragmatic balance between safeguarding proprietary innovation and ensuring affordable supply, particularly during health emergencies. Mechanisms such as technology transfer partnerships, tiered pricing models and access-oriented clauses in licensing agreements play an increasingly prominent role in broadening distribution. Ongoing debate focuses on the efficacy of these instruments, the capacity of domestic institutions to employ them and the negotiation dynamics that shape bilateral and multilateral trade agreements. Concrete examples include adaptations in vaccine patent regimes during the COVID-19 pandemic and targeted legal reforms in emerging markets to bolster generic production without undermining long-term research incentives.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Intellectual Property Rights and Global Health Access publication trend

The graph below shows the total number of articles in intellectual property rights and global health access across all publications each year (not limited to Nature Index journals).

Technical terms

TRIPS Agreement: An international legal instrument administered by the World Trade Organization that sets minimum standards for intellectual property protection across member states.

Compulsory licensing: A statutory mechanism permitting a government to authorise generic production of a patented product without the consent of the patent holder, typically to address public health needs.

Patent opposition: A procedural process allowing third parties to challenge the validity of a granted patent, often used to secure access by invalidating unjustified claims.

Global access principles: Policy guidelines adopted by institutions and firms to ensure that innovations, especially in health, are licensed or priced to facilitate availability in low- and middle-income settings.

Investor–State dispute settlement (ISDS): An arbitration mechanism enabling foreign investors to bring claims against host states for alleged breaches of international investment agreements, including those related to intellectual property.

References

1. Implementation and impact of the global access principles at the University of British Columbia: current successes and future challenges. Frontiers in Pharmacology (2023).
2. How to Study Global Lawmaking: Lessons from Intellectual Property Rights and International Health Emergencies. Annual Review of Law and Social Science (2023).
3. THE LEGALITY OF A TRIPS WAIVER FOR COVID-19 VACCINES UNDER INTERNATIONAL INVESTMENT LAW. International and Comparative Law Quarterly (2022).